HIV resistance to reverse transcriptase inhibitors. [Biochem Pharmacol. 1994] - PubMed Result

Search for

Advanced Search (beta)

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Click to change filter selection through MyNCBI.

1: Biochem Pharmacol. 1994 Jan 20;47(2):155-69. Links

HIV resistance to reverse transcriptase inhibitors.

De Clercq E.

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

PMID: 7508227 [PubMed - indexed for MEDLINE]

Related Articles

Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. [Virology. 1993]
Specific HIV-1 reverse transcriptase inhibitors. [J Enzyme Inhib. 1992]
The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors. [Arch Virol Suppl. 1994]
A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150). [Mol Pharmacol. 1993]
Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. [Virology. 1995]
» See all Related Articles...

Patient Drug Information

Nevirapine (Viramune®) Nevirapine is used in combination with other medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS). Nevirapine is in a class of medication...

» read more ...

Display Show